Financial Performance - Net profit attributable to shareholders for the first nine months of 2023 was a loss of CNY 6,294,345.42, a decline of 153.65% year-on-year [11]. - Operating revenue for the first nine months of 2023 increased by 19.80% to CNY 115,156,370.54 compared to the same period last year [11]. - Operating profit for the first nine months of 2023 was CNY -5,107,161.65, a decrease from CNY 12,860,680.46 in the same period of 2022, indicating a decline of 139.7% [45]. - Net profit for the first nine months of 2023 was CNY -5,317,980.32, compared to a net profit of CNY 13,238,039.22 in the same period of 2022, reflecting a significant decrease of 140.1% [46]. - Total comprehensive income for the first nine months of 2023 was CNY -5,317,980.32, compared to CNY 13,238,039.22 in the same period of 2022, reflecting a decline of 140.1% [46]. Assets and Liabilities - Total assets as of September 30, 2023, were CNY 430,201,877.25, a decrease of 0.72% compared to the end of 2022 [11]. - The company's total liabilities to total assets ratio increased to 27.22% from 17.34% year-on-year [11]. - Current liabilities increased significantly to CNY 89,980,029.60 from CNY 45,459,463.92 year-over-year, primarily due to a rise in short-term borrowings [35]. - Non-current liabilities totaled CNY 27,117,915.73, a decrease from CNY 29,679,165.79 in the previous year [35]. - The company has pledged assets totaling CNY 101,342,877.36, which accounts for 23.55% of total assets [29]. Cash Flow - The company's cash flow from operating activities showed a net outflow of CNY 516,918.53, a decrease of 105.72% compared to the previous year [11]. - Cash inflow from operating activities for the first nine months of 2023 was CNY 123,743,294.55, compared to CNY 108,820,631.39 in the same period of 2022, an increase of approximately 13.7% [47]. - Cash outflow for operating activities totaled CNY 122,167,015.95, an increase from CNY 97,196,374.56, reflecting a rise of about 25.7% [51]. - Cash inflow from financing activities totaled CNY 113,000,000.00, down from CNY 181,750,000.00, representing a decline of approximately 37.9% [51]. - The net cash flow from financing activities was CNY 12,861,343.35, compared to CNY 109,024,638.61, a decrease of about 88.2% [51]. Shareholder Information - The total number of unrestricted shares increased from 19,709,700 (35.22%) to 52,704,400 (47.33%) during the reporting period [19]. - The total number of restricted shares decreased from 36,250,300 (64.78%) to 58,656,000 (52.67%) [19]. - The largest shareholder, Yan Heping, holds 53,246,000 shares, representing 47.81% of total shares [21]. - The company reported a total of 11,635 common shareholders at the end of the reporting period [19]. Operational Metrics - The gross profit margin declined due to a higher proportion of lower-margin feed products sold [14]. - Total operating costs for the first nine months of 2023 were CNY 125,215,153.85, compared to CNY 88,834,774.56 in the same period of 2022, an increase of approximately 41.0% [45]. - Research and development expenses for the first nine months of 2023 were CNY 7,749,700.05, consistent with CNY 7,162,008.50 in the same period of 2022, showing a slight increase of 8.2% [45]. Investment and Construction - The company invested significantly in construction projects, with in-progress construction costs rising by 51.53% to CNY 137,542,382.36 [13]. - Deferred income decreased to CNY 27,117,915.73 from CNY 29,679,165.79, indicating a reduction in future revenue obligations [39]. Other Financial Metrics - Non-recurring gains totaled CNY 3,852,085.63, with a net amount of CNY 3,274,272.79 after tax effects [16]. - Cash and cash equivalents decreased from CNY 45,112,911.72 at the end of 2022 to CNY 24,108,136.44 by September 30, 2023 [32]. - Accounts receivable increased from CNY 20,901,640.10 to CNY 25,611,456.69 during the same period [32]. - Inventory decreased slightly from CNY 33,751,160.28 to CNY 32,064,700.84 [32].
大禹生物(871970) - 2023 Q3 - 季度财报